DENVER, CO—Longer-term follow-up data from the ABSORB II and III trials confirm the significantly increased risk of thrombotic events with the Absorb bioresorbable vascular scaffold (BVS; Abbott ...
Using specially synthesized crystalline materials, scientists from the University of Southern Denmark have created a substance that is able to absorb and store oxygen in such high concentrations that ...
‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent
WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...
Abbott Laboratories, one of the biggest makers of coronary stents in the world, is halting global sales of a fully absorbable stent that was once hailed as the next big breakthrough in medical devices ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 2 years after implantation, a fully bioresorbable ...
CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software Inc., a leading provider of cloud-based learning and performance management software for corporations and higher education institutions, announced ...
CALGARY, Alberta, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absorb Software, the leading global AI-driven learning platform provider, announced the launch of mentoring in Absorb LMS, a next-generation ...
Little more than a year after receiving FDA approval for its Absorb Bioresorbable Vascular Scaffold (BVS), Abbott has announced it will stop selling the device. The worldwide discontinuation of sales, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results